Dofetilide in patients with congestive heart failure and left ventricular dysfunction

New England Journal of Medicine

Volumn 341, Issue 12, 1999, Pages 857-865

  Torp Pedersen, Christian ^a   Møller, Mogens ^b   Bloch Thomsen, Poul Erik ^a   Køber, Lars ^a   Sandøe, Erik ^c   Egstrup, Kenneth ^c   Agner, Erik ^d   Carlsen, Jan ^e   Videbæk, Jørgen ^e   Marchant, Bradley ^f   Camm, A John ^g  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c Haderslev Hospital   (Denmark)

^d Nordsjællands Hospital Hillerød   (Denmark)

^e BISPEBJERG HOSPITAL   (Denmark)

^f PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^g ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DOFETILIDE;

ADULT; AGED; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HEART FAILURE, CONGESTIVE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PHENETHYLAMINES; RECURRENCE; SULFONAMIDES; SURVIVAL ANALYSIS; TORSADES DE POINTES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0033575989     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199909163411201     Document Type: Article

References (34)

1. Pardaens K, Van Cleemput J, Vanhaecke J, Fagard RH. Atrial fibrillation is associated with a lower exercise capacity in male chronic heart failure patients. Heart 1997;78:564-8.
2. The Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation. I. Clinical features of patients at risk. Ann Intern Med 1992;116:1-5.
3. Vigna C, Russo A, De Rito V, et al. Frequency of left atrial thrombi by transesophageal echocardiography in idiopathic and in ischemic dilated cardiomyopathy. Am J Cardiol 1992;70:1500-1.
4. Alam M, Thorstrand C. Left ventricular function in patients with atrial fibrillation before and after cardioversion. Am J Cardiol 1992;69:694-6.
5. Lang R, Klein HO, Weiss E, et al. Superiority of oral vcrapamil therapy to digoxin in treatment of chronic atrial fibrillation. Chest 1983;83:491-9.
6. Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure: a study of 390 patients. Circulation 1991;84:40-8.
7. Flaker GC, Blackshear JL, McBride R, Kronmal RA, Halperin JL, Hart RG. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992;20:527-32.
8. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized control trials. Circulation 1990; 82:1106-16.
9. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodaronc in severe congestive heart failure. Lancet 1994;344:493-8.
10. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;333:77-82.
11. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997;30:791-8.
12. Gwilt M, Arrowsmith JE, Blackburn KJ, et al. UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. J Pharmacol Exp Ther 1991;256:318-24.
13. Friedrich T, Nichols DJ, Alabaster CT, Roden DM. Dofetilide. In: Messerli F, ed. Cardiovascular drug therapy. Philadelphia: W.B. Saunders, 1996:1296-303.
14. Carmeliet E. Voltage- and time-dependent block of the delayed K+ current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther 1992;262: 809-17.
15. Nademanee K, Bailey WM, O'Neill G, Satler C, Friedrich T, Sharma A. Electrophysiologic and hemodynamic effects of dofetilide in patients with depressed left ventricular function: a randomized, double-blind, placebo-controlled study. PACE 1998;21:867. abstract.
16. Sedgwick ML, Rasmussen HS, Cobbe SM. Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris. Am J Cardiol 1992;69: 513-7.
17. Green MS, Dorian P, Roy D, et al. A randomized, double-blind, placebo-controlled comparison of intravenous dofetilide and procainamide in the acute conversion of atrial fibrillation/flutter. Circulation 1997;96: Suppl:I-453-I-454. abstract.
18. Singh SN, Berk MR, Yellen LG, et al. Efficacy and safety of oral dofetilide in maintaining normal sinus rhythm in patients with atrial fibrillation/flutter: a multicenter study. Circulation 1997;96:Suppl:I-383. abstract.
19. The DIAMOND Study Group. Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design, and patient characteristics of the DIAMOND studies. Clin Cardiol 1997;20:704-10.
20. Køber L, Torp-Pedersen C, Carlsen J, Videbaek R, Egeblad H. An echocardiographic method for selecting high risk patients shortly after acute myocardial infarction, for inclusion in multi-centre studies. Eur Heart J 1994;15:1616-20.
21. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 1989;2:358-67.
22. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
23. Greene HL, Richardson DW, Barker AH, et al. Classification of deaths after myocardial infarction as arrhythmic or nonarrhythmic. Am J Cardiol 1989;63:1-6.
24. Greenbaum R, Campbell TJ, Channer KS, et al. Conversion of AF and maintenance of sinus rhythm by dofetilide. Eur Heart J 1998;19:Suppl: 661. abstract.
25. Deedwania PC, Singh BN, Ellenbogen K, Fisher S, Fletcher R, Singh SN. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the Veterans Affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT), Circulation 1998;98:2574-9.
26. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. N Engl J Med 1991;324:781-8.
27. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12.
28. Garguichevich JJ, Ramos JL, Gambarte A, et al. Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias: Argentine Pilot Study of Sudden Death and Amiodarone (EPAMSA). Am Heart J 1995;130:494-500.
29. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. Lancet 1997;349:667-74.
30. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Lancet 1997;349:675-82.
31. Køber L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolaprit in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333:1670-6.
32. Køber L, Torp-Pedersen C. Clinical characteristics and mortality of patients screened for entry into the Trandolapril Cardiac Evaluation (TRACE) Study. Am J Cardiol 1995;76:1-5.
33. Pratt CM, Camm AJ, Cooper W, et al. Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die? Am J Cardiol 1998; 81:869-76.
34. Freedman MD, Somberg JC. Pharmacology and pharmacokinetics of amiodarone. J Clin Pharmacol 1991;31:1061-9.